Kornimate/medical-research-clean huggingface dataset:
high flow nasal oxygen versus usual care in copd pulmonary rehabiliation

Conditions: Chronic Obstructive Pulmonary Disease

Summary: to compare the effects of high flow nasal oxygen with usual care during an outpatient 6-week pulmonary rehabilitation program after hospitalization for copd exacerbation.

this is a pilot randomized controlled trial to compare the effects of high flow nasal oxygen with usual care during an outpatient 6-week pulmonary rehabilitation program after hospitalization for copd exacerbation.

Eligibility criteria:
inclusion criteria: 1. age 21 years and above 2. known diagnosis of copd based on history and spirometry demonstrating post bronchodilator fev1/fvc ratio \<0.7 3. currently admitted inpatient for an acute copd exacerbation as the primary diagnosis 4. fit to participate in exercise therapy as determined by both physician and physiotherapist 5. has the mental capacity to follow instructions 6. experience shortness of breath on exertion 7. have decreased ability to carry out activities due to shortness of breath 8. willing to participate in the exercise program exclusion criteria: 1. uncontrolled/ unstable medical conditions such as severe chronic heart failure that make exercise unsafe 2. pulmonary disorder other than copd 3. physical conditions that preclude the ability to participate in exercise or may impair exercise performance.
a screening study to detect braf v600 mutation-positive patients for enrollment into clinical research studies of zelboraf (vemurafenib)

Conditions: Multiple Myeloma, Neoplasms

Summary: this is a screening study to detect braf v600 mutation-positive patients for enrollment into clinical research studies of zelboraf (vemurafenib). tumor samples will be collected and analyzed from eligible patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma. all institutions with identified patients as defined by this screening protocol will have potential access to the separate vemurafenib protocol mo28072.


Eligibility criteria:
inclusion criteria: * histologically confirmed solid tumors (excluding melanoma and papillary thyroid cancer) or multiple myeloma refractory to standard therapy or for which standard or curative therapy does not exist or is not considered appropriate by the investigator * patients with multiple myeloma must have received at least one line of prior systemic therapy for the treatment of multiple myeloma exclusion criteria: * eastern cooperative oncology group (ecog) performance status \> 2 * uncontrolled concurrent malignancy * active or untreated cns metastases * history of known carcinomatous meningitis * prior treatment with a braf or mek inhibitor (prior sorafenib is allowed) * uncontrolled, severe medical illness or condition as defined in protocol mo28072
sildenafil therapy for subjects who derive clinical benefit from continued treatment with sildenafil

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to provide sildenafil therapy for subjects who completed a1481156 study and are judged by the investigator to derive clinical benefit from continued treatment with sildenafil, prior to reimbursement and availability for subjects in the russian federation.


Eligibility criteria:
inclusion criteria: * patients who completed study a1481156 and are judged by the investigator to derive clinical benefit from continued treatment with sildenafil, prior to reimbursement and availability for subjects in russian federation. * child bearing age women should have appropriate contraception. * signed informed consent. patients who have a wish and possibility to follow treatment regimens in terms of the study. exclusion criteria: * pregnant and lactating women. * participation in other studies in the current moment or during study period except of a1481156. * patients with severe acute or chronic diseases psychiatric disorders or laboratory abnormalities.

Keywords: sildenafil pulmonary arterial hypertension pah
recurrence of liver malignancy after ischemia/reperfusion injury

Conditions: Ischemic Reperfusion Injury; Liver Injury; Cancer Recurrence; Malignancy; Liver Cancer

Summary: severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. our study aimed at assessing the effect of warm ischemic/reperfusion (i/r) injuries on surgery-to-local recurrence interval and patient overall survival, during major hepatectomies under inflow and outflow vascular control.

one hundred and eighteen patients were subjected to liver resection under total inflow and outflow vascular clamping and were assigned as study group. these individuals were retrospectively matched to 112 counterparts, who underwent liver surgery applying inflow and outflow vascular clamping only of the segment harboring the tumor, sparing the liver remnant from any i/r injury (control group). the two cohorts were compared regarding recurrence-free survival and overall survival.

Eligibility criteria:
inclusion criteria: * adult patients * american society of anesthesiologists (asa) distribution i to iii * patients scheduled for major liver resection (≥3 segments) exclusion criteria: * patients with extrahepatic disease * patients with metastatic liver tumors

Keywords: ischemia reperfusion injury liver surgery cancer recurrence malignancy hepatectomy
effects of self-administered acupressure in psychiatric patients with constipation

Conditions: Constipation

Summary: this study is to evaluate the effects of self-administered acupressure therapy for psychiatric in-patients with constipation two main research questions include: 1. what are the effects of the standardized self-administered acupressure program on reducing those adult psychiatric patients' symptoms of constipation? 2. what are the psychiatric patients' (participants') perceived benefits and limitations of self-administered acupressure on management of their constipation? in this study, the participants who met the study criteria and completed the baseline measurement would be randomly assigned into either the self-administered acupressure program, or a sham control group who receive a placebo, non-acupoint pressure. the null hypotheses of this study are: 1. there is no significant difference between the acupressure and sham group immediately and/or two weeks after the completion of intervention on patients' symptom severity of constipation; and 2. there is no significant difference between the acupressure and sham group on patients' perceived quality of life at immediately and two weeks after treatment completion.

main outcomes of this study include the constipation assessment scale (cas), patient assessment constipation quality of life questionnaire (pac-qol), and the socio-demographic and clinical data collected by a trained assessor who was blind to the intervention assignment of the participants. these data would be measured at recruitment (baseline) and immediately (post-test 1) and two weeks (post-test 2) after completion of the 10-day intervention. qualitative focus group interview data would be collected after post-test 2 .

Eligibility criteria:
inclusion criteria of psychiatric in-patients are: 1. hong kong chinese residents, aged 18 to 64 years; 2. satisfied with rome iii diagnostic criteria for constipation; and 3. mentally stable and competent for self-care and learning acupressure, as recommended by their attending psychiatrists. exclusion criteria of those in-patients are: 1. anatomical and physiological disorders of gastrointestinal tract such as malrotation, fistula and colonic neuropathies; 2. metabolic and endocrine diseases; 3. lead poisoning and vitamin d intoxication; 4. previous training in acupressure; 5. physical disability involved the upper limbs; 6. planned surgery undergoing during study period; and 7. pregnancy.

Keywords: acupressure self-administration psychiatric in-patients constipation self-administered acupressure program sham control group
anti inflammatory treatment of hypertension

Conditions: Hypertension

Summary: to investigate the anti-inflammatory effect of amlodipine and levamlodipine in the treatment of hypertension

a total of 200 inpatients or outpatients in the department of cardiovascular medicine of the third people's hospital of mianyang city from april 2021 to october 2021, who met the diagnostic criteria of ish2020 international hypertension practice guidelines, were selected and randomly divided into control group and experimental group, with 100 cases in each group. the control group was treated with amlodipine and the experimental group was treated with levoamlodipine. the changes of blood pressure and serum inflammatory factors were observed before and after treatment.

Eligibility criteria:
inclusion criteria: * ① in line with the diagnostic criteria of ish2020 international guidelines for practice of hypertension ② age \>18 years old, gender is not limited, during the treatment did not take other drugs that will affect blood pressure: such as antidepressants, oral contraceptives, chinese herbal medicine, etc.; voluntary participation and signing of informed consent, and can complete all the visit plan. exclusion criteria: * (1) those who do not want to take blood tests; (2) left ventricular ejection fraction \< 50%, heart rate \<50 beats/min; ③ acute coronary syndrome (unstable angina pectoris and myocardial infarction); ④ valvular heart disease, congenital heart disease, etc.; other infectious diseases and malignant tumors; ⑥ bronchial asthma; ⑦ abnormal liver function and renal dysfunction (alt bbb 0 80u/l, cr bbb 1 442mmol/l); autoimmune diseases or any serious and fatal diseases; ⑨ receiving lipid-lowering therapy and oral vitamins or antioxidants; they are mentally ill, have no self-awareness, and are unable to express themselves or cooperate with others.

Keywords: levamlodipine amlodipine serum inflammatory factors anti inflammatory treatment
e-counseling promotes blood pressure reduction and therapeutic lifestyle change in hypertension

Conditions: Hypertension

Summary: this proposed clinical trial, reach, will enroll 538 persons with hypertension. all subjects will continue with their prescribed medications. our main objective is to assess whether preventive e-counseling (provided through a website of the heart and stroke foundation) improves blood pressure and cardiovascular risk status over a 12-month interval. reach will also evaluate improvement in lifestyle behaviors that include diet, exercise, smoking, and adherence to prescribed medications. finally, we will quantify the amount of e-counseling support that is required during reach to evoke a significant reduction in blood pressure. it is hypothesized that e-counseling (vs. control) will significantly improve blood pressure and lifestyle behaviours at the 12-month assessment. the findings of this trial will provide information that is critical to our understanding of how internet-based programs can help to improve blood pressure and to reduce the risk for cardiovascular disease.


Eligibility criteria:
inclusion criteria: * age: 35-74 years * diagnosis of hypertension: medication or physician confirmation * baseline bp in lab: \>=140/90 (if no meds); \>=130/85 (if on meds) * if medications, prescription unchanged \>=2 months comprehension of english (oral and written) exclusion criteria: * diagnosis of clinically significant arrhythmia, sleep apnea, kidney disease, major psychiatric illness (eg. psychosis), alcohol or drug dependence in the previous year; institutional residence, or an inability to comprehend english
effect of cryotherpy on hypertrophic scar

Conditions: Hypertrophic Scars

Summary: purpose of the study: the purpose of the study is to evaluate the therapeutic effect of cryotherpy in treating hypertrophic scar. it will be hypothesized that: cryotherapy may not have an effect on hypertrophic scar.

the potential of cryotherapy application in vitro data indicated that using freezing treatment on vffs + tgf-β1 (myofibroblast) modulated ecm turnover toward antifibrosis and normalization, attenuated myofibroblast differentiation, reduced cell migration, and weakened the contractile activity. on both vffs ± tgf-β1, freezing treatment raised lp regeneration (has1, decorin). the findings indicate that cryotherapy may play a protective role in scar formation and contribute to lamina regeneration. furthermore the need of this study was developed from the lack in the quantitative knowledge and information in the published studies about the effect of cryotherapy on hypertrophic scar. this study will be designed to provide a guideline about the effect of effect of cryotherapy on hypertrophic scar height, thickness and discoloration, and to assist in planning an ideal treatment regimen for reducing hypertrophic scar. delimitations: this study will be delimited in the following aspects: 1. subjects: sixty patients suffering from hypertrophic scar will be randomly divided into two equal groups each one has 30 patients. 2. equipment and tools: 2.1. measurement equipment: vancouver scar scale. maps (matching assessment of scars and photographs). 2.2. therapeutic equipment: gymna cryoflow ice-ct. temperature resistant polymide tape (48 wide). hypothesis: it will be hypothesized that: cryotherapy may not have an effect on hypertrophic scar. basic assumptions: it will be assumed that: * all patients will receive the same kinds of medication and the same nursing care. * all subjects are free from any chronic disease. * all subjects will continue in the study. * all patients will follow the instructions during the treatment

Eligibility criteria:
inclusion criteria: * age range between 20- 40 years. * both sexes will participate in the study. * all patients participated will begin treatment program one month after injury depending on injury characteristics. * all patients enrolled to the study will have their informed consent. exclusion criteria: * diabetes mellitus. * individuals with cardiopulmonary conditions. * individuals undergoing radiation therapy or chemotherapy. * hepatic or pancreatic diseases. * sensory impairment
prospective evaluation of keat electrostimulator in the auto-reeducation of female urinary incontinence

Conditions: Urinary Incontinence

Summary: the investigators performed a prospective analysis of 450 women with stress, urge and mixed incontinence in order to assess the health-related quality of life (contilife® questionnaire) and the objective cure rate after two months of electrical stimulation (keat® stimulator). management of urinary incontinence with the keat® stimulator could given an improvement in the quality of life and a good rate of satisfaction without side effect. objective cure is as good as subjective improvement especially in urinary stress incontinence. keat® stimulator is a non-invasive and simple new technique that could be the bew first-line non surgical treatment for female urinary incontinence.


Eligibility criteria:
inclusion criteria: * women * age \> 18 years * stress, urge or mixed incontinence with indication of perineal reeducation * follow in gynecology exclusion criteria: * incontinence due to neurological disorders * younger than 18 years old * pregnancy * patient with pace-maker * patient with gynecological cancer * patient who don't understand the electrical stimulation procedure

Keywords: urinary incontinence urinary stress incontinence urinary urge incontinence women electrical stimulation keat stimulator quality of life
clarithromycin, sulfamethoxazole/trimethoprim or observation in newly diagnosed multiple myeloma

Conditions: Multiple Myeloma; Infection

Summary: this study evaluates the effect of prophylactic antibiotics in multiple myeloma. one third of patients will received treatment with clarithromycin, one third of patients will receive treatment with sulfamethoxazole/trimethoprim and one third will be observed without prophylactic antibiotics. all patients receive concurrent anti-myeloma treatment.

there is a need for improvement of the prognosis in elderly myeloma patients. the patients are fragile due to age and severe comorbidity. infections are frequent during the course of initial myeloma treatment and contribute to the high morbidity and mortality in elderly patients. furthermore infections often lead to delay in myeloma treatment and to dose reduction. the use of primary antibiotic prophylaxis might influence the frequency of these complications. in the study myeloma patients who are ineligible for high-dose melphalan with stem cell support are randomised to either p.o. clarithromycin 250 mg twice daily for 180 days, p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days or observation without prophylactic antibiotics. all patients receive concurrent myeloma treatment at the discretion of the treating physician. the choice of anti-myeloma treatment has to be settled before randomization. the study evaluates the frequency of infections in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observation

Eligibility criteria:
inclusion criteria: * myeloma diagnosis according to imwg criteria * treatment demanding disease * signed informed consent given prior to any study related activities, except bone marrow samples for diagnosis, fish, biobanking, and skeletal x-ray * age \> 18 years exclusion criteria: * allogeneic transplantation scheduled as a part of the treatment * high-dose melphalan with stem cell support scheduled as a part of the treatment * myeloma treatment prior to entry in the study, except radiotherapy, bisphosphonates/denusumab or corticosteroids for symptom control * concurrent disease making clarithromycin or sulfamethoxazole/trimethoprim treatment unsuitable * positive pregnancy test (only applicable for women with childbearing potential) * known or suspected hypersensitivity or intolerance to claritromycin, sulfamethoxazole or trimethoprim * prolonged qt corrected (qtc) interval ( \> 500 msec on screening ecg) * concurrent treatment with cabergoline, fluconazole, ketoconazole, pimozide, quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid or methotrexate * uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, uncontrolled angina or known cardiac amyloidosis * severe renal dysfunction (estimated creatinine clearance \<10 ml/min) * serious medical or psychiatric illness which, in the judgment of the investigator, would make the patient inappropriate for entry into the study

Keywords: multiple myeloma infection clarithromycin trimethoprim-sulfamethoxazole combination
safety, tolerability and pharmacokinetics (pk) evaluation of bz371a, topically administered

Conditions: Erectile Dysfunction Following Radical Prostatectomy; Erectile Dysfunction; Prostate Cancer; Radical Prostatectomy

Summary: the purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of bz371a topically administered in healthy patients.

prostate cancer remains one of the most prevalent cancer in men. for its treatment, recent technological advances demonstrate that the most effective treatment is the radical prostatectomy (rp) procedure. however, although curative for prostate cancer, can result in damage to the cavernosal nerves. the cavernosal autonomic nerves travel posterolaterally to the prostate to enter the penis and regulate blood flow and hence erection. thus, damage caused by rp will affect no tissue release and blood flow regulation, causing erectile dysfunction. bz371a has the ability to restore local blood flow regulation by a new and innovative mechanism of action and, therefore, has potential to be a supportive therapy for rp patients (restoring the erectile function). thus, this study has the purpose to evaluate safety, tolerability and pharmacokinetics of a bz371a single dose, topically administrated at the genital area.

Eligibility criteria:
inclusion criteria: * men or women * body mass index \> 19 and \< 28.5 kg/m2 * is able to understand the informed consent form (icf) exclusion criteria: * women in their menstrual period; * diseases that interfere with the absorption, distribution and excretion of drugs, such as history or presence of hepatic or renal diseases; * presence of active genital lesions or sexually transmitted disease (std) (such as herpes, gonorrhea, candidiasis, human papillomavirus, and others) that impair analysis of local adverse effects on the genitalia; * history of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patients with heart disease (including a history of angina and/or heart failure) and nephropathies; * findings on ecg and/or laboratory tests that, in the investigator's judgment, are considered the research volunteer's participation or may interfere with the analysis of the study of the study; * blood pressure (bp) outside the limits considered safe: systolic bp (sbp) 90 - 140 mmhg and diastolic bp diastolic bp (dbp) 60 - 90 mmhg, except for situations such as "white coat syndrome"; * any disease or condition or physical finding that the investigator considers significant and that increases the risk * any disease or condition or physical finding that the investigator considers significant and that increases the risk of participation of the research volunteer or may interfere with the results.

Keywords: erectile dysfunction radical prostatectomy prostate cancer